Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharma company Regeneron
So what: Just yesterday Regeneron shares were soaring thanks to positive data from the company's Zaltrap drug. Today, they were giving some of those gains back as investors chewed on some data out of the National Eye Institute. The NEI found that Roche's drug Avastin worked just as well treating macular degeneration as the company's more expensive drug, Lucentis. Reuters reported that both Roche and Novartis
Now what: While this has obvious implications for Roche and Novartis, Regeneron is currently working on its own macular-degeneration treatment -- VEGF Trap-Eye -- with Bayer. Should Avastin and its bargain price tag become an accepted treatment, it'd hardly be ideal for Regeneron. In the NEI study, there were more side effects reported from Avastin than Lucentis, but researchers said that the study wasn't large enough to confirm that the side effects were directly tied to Avastin. Regeneron shareholders will want to keep an eye on how this situation continues to develop.
Want to keep up to date on these stocks?
Novartis AG is a Motley Fool Global Gains pick. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.